Roberto Borea, MD (@RobertoBoreaMD) ranks #36 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 5 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: ARTEMIS-008, TAISHAN-302, ASTRIDE. This profile quotes their 4 trial posts from 2026 word for word, with links to the originals on X.
At a Glance
- 4 posts naming a trial in 2026
- 3 trials discussed by name
- Lung Cancer: US #36 · 5 physicians engaged
- Leading physician voice: #3 of 7 physicians on ASTRIDE
- Presented at WCLC 2026 in 2026
This Month
What Roberto Borea, MD has posted in the last 30 days. Updated November 10, 2026.
Congrats to @drgandara on presenting ASTRIDE at #ESMO26! Randomized bridging trial in US pts with ES-SCLC: serplulimab vs atezolizumab + chemo -mOS 12.4 vs 10.2 mo (HR 0.82) -24-mo OS 32.2% vs 17.6% -Similar safety Supports ASTRUM-005 findings in US pts @myESMO @isliquidbiopsy https://t.co/QqD3ZuWlsD
Who Amplifies Roberto Borea, MD
Physicians who reposted Roberto Borea, MD’s trial posts most often in 2026.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #36 | — | 5 | 6 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Roberto Borea, MD presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- WCLC 2026 · Abstract presentationWhole transcriptomics analysis in patients with early NSCLC to predict risk of recurrenceSource: @ChristianRolfo on X ↗
- WCLC 2026 · PosterObesity paradox in patients with NSCLC treated with TKIsSource: @RobertoBoreaMD on X ↗
What Colleagues Are Saying About Roberto Borea, MD
2026 posts by fellow physicians that mention @RobertoBoreaMD, quoted word for word.
Excellent presentation by @RobertoBoreaMD at #WCLC26 on our work on whole transcriptomics analysis in pts with early NSCLC to predict risk to recurrence. Opening the door for personalize adjuvant treatment. @OhioStateMedOnc @OSUCCC_James @rolfolab @GianniNigita @IASLC https://t.co/H3ekFTuFTQ
Trials Roberto Borea, MD Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| ARTEMIS-008 | 2 | #15 of 20 | Sep 13, 2026 |
| TAISHAN-302 | 2 | #19 of 26 | Sep 13, 2026 |
| ASTRIDE | 1 | #3 of 7 | Oct 26, 2026 |
Roberto Borea, MD on ARTEMIS-008
Terrific discussion by #AnneChang at #WCLC2026 on ADCs in SCLC @IASLC TAISHAN-302 and ARTEMIS-008 both show clear OS/PFS benefit over topotecan, pointing to a possible new standard. Manageable toxicity overall Looking forward a bright ADC future 💡 https://t.co/NKTnmMi1pL
ARTEMIS-008 Risvutatug Rezetecan vs Topotecan in relapsed SCLC OS • Median OS: 18.5 vs 10.3 months • HR 0.46 (95% CI 0.35–0.62), p < 0.0001 Key secondary • BICR-PFS: 7.2 vs 3.0 months (HR 0.33) Potential new SoC . #WCLC2026 @IASLC https://t.co/luDmhsPhbC
Roberto Borea, MD on TAISHAN-302
Terrific discussion by #AnneChang at #WCLC2026 on ADCs in SCLC @IASLC TAISHAN-302 and ARTEMIS-008 both show clear OS/PFS benefit over topotecan, pointing to a possible new standard. Manageable toxicity overall Looking forward a bright ADC future 💡 https://t.co/NKTnmMi1pL
TAISHAN-302: Phase 3 trial of Tam-Peli (B7-H3 ADC) vs topotecan in relapsed SCLC (N=451) after platinum therapy. OS: 13.3 vs 9.4 months (HR 0.46), 54% reduction in risk of death. Safety profile favorable and manageable #WCLC26 @IASLC https://t.co/4wJT1Pjpnv
Roberto Borea, MD on ASTRIDE
Congrats to @drgandara on presenting ASTRIDE at #ESMO26! Randomized bridging trial in US pts with ES-SCLC: serplulimab vs atezolizumab + chemo -mOS 12.4 vs 10.2 mo (HR 0.82) -24-mo OS 32.2% vs 17.6% -Similar safety Supports ASTRUM-005 findings in US pts @myESMO @isliquidbiopsy https://t.co/QqD3ZuWlsD
Roberto Borea, MD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
Liquid biopsy abstracts I would not miss at #ESMO26 in Madrid 🩸 17 abstracts: ctDNA dynamics on targeted therapy, ctDNA clearance with perioperative IO, ultrasensitive MRD, early detection, MCED, and much more @isliquidbiopsy @UmbertoMalapel1 @ChristianRolfo @myESMO @OncoAlert https://t.co/VLRUWTHe0H
Honored to receive feedback and a visit from @KimrynRathmell, CEO of @OSUCCC_James, and my mentor @ChristianRolfo on our study on the obesity paradox in #NSCLC at #AACR26🎯 Thank to @GianniNigita and all the @rolfolab team to supporting me in this project! @OhioStateMedOnc https://t.co/rvTat9m9BD
🔬 Our work on whole-transcriptome profiling for metastatic recurrence prediction in early-stage NSCLC will be presented as an oral presentation at #WCLC2026 in Seoul. Grateful to @ChristianRolfo for his mentorship in advancing precision oncology. @OSUCCC_James @IASLC https://t.co/tea6SOG59Y
My great colleague @IshwarSan22 stopping by our #Midkine poster at #AACR26! 🙌 He has been guiding me through this journey and his support has been invaluable. So grateful to have such an incredible colleague by my side! @ChristianRolfo @OhioStateMed @OSUCCC_James #NSCLC https://t.co/CeRaPrnqWp
🔬 Magistral plenary presentation by @JeanneTie on the clinical utility of MRD at #AACR26! Redefining how we monitor and choose the best treatment in the era of precision medicine! 🎯 @isliquidbiopsy @rolfolab https://t.co/uev6NYwiuw